From Joe Shan's commentary on the 7/16 conference call:
It is extremely encouraging that the MOS then, and even to date, has not yet been reached in either of the bavituximab-containing arms, with some patients continuing to receive bavituximab maintenance. This trial will remain open to collect survival follow-up until at least a median number.........
Any thoughts on "Bavituximab maintenance"? Dosage, frequency, patient criteria? I haven't heard much about this possible use for Bavi. Would certain patient populations be put on a maintenance dose of Bavi to prrevent further progression of their illness?